X4 Pharmaceuticals announced its Q1 2026 financial results, reporting a net loss of $20.2 million due to lower license revenue compared to 2025. The company highlighted the European Commission's approval of XOLREMDI® (mavorixafor) as the first authorized treatment for WHIM syndrome in the EU, with commercialization led by partner Norgine. Enrollment in the global 4WARD Phase 3 trial for chronic neutropenia is on track to complete by the end of Q3 2026. X4 maintains a strong cash position of $233.7 million, supporting operations through 2028.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
